Alpha Cognition logo
Alpha Cognition
ACOG | NASDAQ
Chart Builder DCF Calculator
$7.83
-$0.47 (-5.66%)
At close: Nov 16, 2026, 4:00 PM ET
$7.83
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Alpha Cognition Company Profile

Company profile explained

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Key Executives

Name Position
Michael E. McFadden Chief Executive Officer & Director
Henry Du Vice President of Finance & Accounting and Interim Chief Financial Officer
Lauren D'Angelo Chief Operating Officer
Christine Reveal Vice President of Marketing & Commercial Strategy
Denis G. Kay Chief Scientific Officer
Kenneth Anthony Cawkell Founder, Consultant, Corporate Secretary & Director
Timothy Ayers Head of Compliance

Latest SEC Filings

Date Type Title
Oct 26, 2026 4 Filing
Oct 19, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 23, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 16, 2026 4 Filing
Aug 24, 2026 4 Filing
Aug 13, 2026 10-Q Quarterly Report
Aug 04, 2026 4 Filing
Jul 28, 2026 4 Filing
View All SEC Filings ➞
Alpha Cognition
Alpha Cognition logo
Country United States
IPO Date Nov 12, 2024
Industry Biotechnology
Sector Healthcare
Employees 71
CEO Michael E. McFadden

Contact Details

1452 Hughes Street Grapevine, Texas 76051 United States

Stock Details

Ticker Symbol ACOG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001655923
CUSIP Number 02074J501
ISIN Number CA02074J5017
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.